Showing results (1-10 of 584) with videos related to
Sort By:
Pageof 59
Therapeutics and Clinical Risk Management|May 14, 2008
Targeting CD22 as a strategy for treating systemic autoimmune diseasesThomas Dörner, David M GoldenbergAutoimmunity Reviews|July 28, 2015
The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosusThomas Dörner, Anthony Shock, David M Goldenberg, et al.Arthritis Research & Therapy|April 25, 2006
Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosusThomas Dörner, Joerg Kaufmann, William A Wegener, et al.Arthritis Research & Therapy|September 6, 2011
Challenges in understanding Sjögren's syndrome--improved insights into the pathogenesis generate hope for innovative therapies?Thomas DörnerThe Journal of Rheumatology. Supplement|May 3, 2006
Crossroads of B cell activation in autoimmunity: rationale of targeting B cellsThomas DörnerNature Reviews. Rheumatology|January 11, 2012
SLE in 2011: Deciphering the role of NETs and networks in SLEThomas DörnerArthritis Research & Therapy|November 6, 2010
Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosusCapucine Daridon, Daniela Blassfeld, Karin Reiter, et al.Arthritis Research & Therapy|March 13, 2012
The anti-CD74 humanized monoclonal antibody, milatuzumab, which targets the invariant chain of MHC II complexes, alters B-cell proliferation, migration, and adhesion molecule expressionDaniela Frölich, Daniela Blassfeld, Karin Reiter, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 8, 2002
Targeted therapy of cancer with radiolabeled antibodiesDavid M GoldenbergExpert Review of Anticancer Therapy|October 31, 2006
Epratuzumab in the therapy of oncological and immunological diseasesDavid M GoldenbergPageof 59